Concurrent combination chemotherapy of human solid tumors: experience with a three-drug regimen and review of the literature.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000187:drug effects*; D001859:Bone Neoplasms / Q000188:drug therapy; D002277:Carcinoma / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000009:adverse effects; D003609:Dactinomycin / Q000009:adverse effects; D004357:Drug Synergism; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008558:Melphalan / Q000009:adverse effects*; D008875:Middle Aged; D008937:Mitomycins / Q000009:adverse effects*; D010307:Parotid Neoplasms / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy*; D014565:Urogenital Neoplasms / Q000188:drug therapy; D014750:Vincristine / Q000009:adverse effects*
D008937:Mitomycins; D003609:Dactinomycin; D014750:Vincristine; D003520:Cyclophosphamide; D008558:Melphalan; D005472:Fluorouracil